Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Hemocompatibility of liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the lipid bilayer.

Kuznetsova NR, Sevrin C, Lespineux D, Bovin NV, Vodovozova EL, Mészáros T, Szebeni J, Grandfils C.

J Control Release. 2012 Jun 10;160(2):394-400. doi: 10.1016/j.jconrel.2011.12.010.

PMID:
22210161
2.

Differential binding of plasma proteins by liposomes loaded with lipophilic prodrugs of methotrexate and melphalan in the bilayer.

Kuznetsova NR, Vodovozova EL.

Biochemistry (Mosc). 2014 Aug;79(8):797-804. doi: 10.1134/S0006297914080070.

4.

Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment.

Srisuk P, Thongnopnua P, Raktanonchai U, Kanokpanont S.

Int J Pharm. 2012 May 10;427(2):426-34. doi: 10.1016/j.ijpharm.2012.01.045.

PMID:
22310459
5.

[Liposome formulations of combretastatin A4 and 4-arylcoumarin analog prodrugs: antitumor effect in the mouse model of breast cancer].

Mouseeva EV, Kuznetsova NR, Svirshchevskaia EV, Bovin NV, Sitnikov NC, Shavyrin AS, Beletskaia IP, Combes S, Fedorov AIu, Vodovozova EL.

Biomed Khim. 2012 May-Jun;58(3):326-38. Russian.

PMID:
22856138
6.

Interactions of antitumour Sialyl Lewis X liposomes with vascular endothelial cells.

Alekseeva A, Kapkaeva M, Shcheglovitova O, Boldyrev I, Pazynina G, Bovin N, Vodovozova E.

Biochim Biophys Acta. 2015 May;1848(5):1099-110. doi: 10.1016/j.bbamem.2015.01.016.

7.

[Liposomal formulation of a methotrexate diglyceride conjugate: activity in methotrexate-resistant leukemia cultured cells].

Vodovozova EL, Kuznetsova NR, Gaenko GP, Molotkovskiĭ IuG.

Bioorg Khim. 2007 Jul-Aug;33(4):470-3. Russian.

PMID:
17886439
8.

Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity.

Prabhu P, Shetty R, Koland M, Vijayanarayana K, Vijayalakshmi KK, Nairy MH, Nisha GS.

Int J Nanomedicine. 2012;7:177-86. doi: 10.2147/IJN.S25310.

9.

The role of nanoparticle size in hemocompatibility.

Mayer A, Vadon M, Rinner B, Novak A, Wintersteiger R, Fröhlich E.

Toxicology. 2009 Apr 28;258(2-3):139-47. doi: 10.1016/j.tox.2009.01.015.

PMID:
19428933
10.

Prolonged blood circulation of methotrexate by modulation of liposomal composition.

Hong MS, Lim SJ, Lee MK, Kim YB, Kim CK.

Drug Deliv. 2001 Oct-Dec;8(4):231-7.

PMID:
11757781
11.

[Effect of acetylsalicylic acid in complex with lipid nanostructures of various compositions on human platelet aggregation].

Suslina ZA, Prokhorov DI, Shilova AG, Kaplun AP, Ionova VG, Seĭfulla RD.

Eksp Klin Farmakol. 2011;74(5):31-4. Russian.

PMID:
21809695
12.

Toxicity of gamma irradiated liposomes. 1. In vitro interactions with blood components.

Stensrud G, Passi S, Larsen T, Sandset PM, Smistad G, Mönkkönen J, Karlsen J.

Int J Pharm. 1999 Feb 1;178(1):33-46.

PMID:
10205623
13.

Targeting liposomes loaded with melphalan prodrug to tumour vasculature via the Sialyl Lewis X selectin ligand.

Kuznetsova NR, Stepanova EV, Peretolchina NM, Khochenkov DA, Boldyrev IA, Bovin NV, Vodovozova EL.

J Drug Target. 2013 Dec 9. [Epub ahead of print]

PMID:
24313904
14.

Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction.

Szebeni J, Baranyi L, Savay S, Bodo M, Morse DS, Basta M, Stahl GL, Bünger R, Alving CR.

Am J Physiol Heart Circ Physiol. 2000 Sep;279(3):H1319-28.

15.

Haemolytic activity of liposomes: effect of vesicle size, lipid concentration and polyethylene glycol-lipid or arsonolipid incorporation.

Mourtas S, Michanetzis GP, Missirlis YF, Antimisiaris SG.

J Biomed Nanotechnol. 2009 Aug;5(4):409-15.

PMID:
20055087
16.

Exploring the fate of liposomes in the intestine by dynamic in vitro lipolysis.

Parmentier J, Thomas N, Müllertz A, Fricker G, Rades T.

Int J Pharm. 2012 Nov 1;437(1-2):253-63. doi: 10.1016/j.ijpharm.2012.08.018.

PMID:
22939968
17.

In-vitro stability and cytostatic activity of liposomal formulations of 5-fluoro-2'-deoxyuridine and its diacylated derivatives.

van Borssum Waalkes M, van Galen M, Morselt H, Sternberg B, Scherphof GL.

Biochim Biophys Acta. 1993 May 14;1148(1):161-72.

PMID:
8499464
18.

Influence of microenvironment and liposomal formulation on secondary structure and bilayer interaction of lysozyme.

Witoonsaridsilp W, Panyarachun B, Sarisuta N, Müller-Goymann CC.

Colloids Surf B Biointerfaces. 2010 Feb 1;75(2):501-9. doi: 10.1016/j.colsurfb.2009.09.027.

PMID:
19880295
19.

Formation and finite element analysis of tethered bilayer lipid structures.

Kwak KJ, Valincius G, Liao WC, Hu X, Wen X, Lee A, Yu B, Vanderah DJ, Lu W, Lee LJ.

Langmuir. 2010 Dec 7;26(23):18199-208. doi: 10.1021/la1021802.

PMID:
20977245
20.

Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.

Gabizon A, Amitay Y, Tzemach D, Gorin J, Shmeeda H, Zalipsky S.

J Control Release. 2012 Jun 10;160(2):245-53. doi: 10.1016/j.jconrel.2011.11.019.

PMID:
22134116

Supplemental Content

Support Center